

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**COALITION FOR AFFORDABLE
DRUGS VII, LLC,**
Petitioner,

v.

**THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA,**
Patent Owner.

Case IPR2015-01835

Patent 8,618,135

**PATENT OWNER'S RESPONSE TO PETITIONER'S
OBSERVATIONS ON CROSS-EXAMINATION OF
DR. THOMAS A. BAILLIE**

Patent Owner hereby files its Response to Petitioner's Observations on Cross-Examination of Dr. Thomas A. Baillie. IPR2015-01835, Paper 41.

Response 1: Petitioner mischaracterizes Dr. Baillie's testimony because he specifically identified the "critical feature" of the invention to be the claimed dosing regimen, which produced unexpected results of adaptation or tolerance to toxicities of concern with lomitapide. CFAD Ex. 1060 at 8:16-10:12. Further, the precise dose escalation factor needed to promote biological adaptation with lomitapide is irrelevant. Although Dr. Rader used dose escalation factors that were more aggressive than twofold in his phase II trial, this does not contradict Dr. Baillie's opinion that the claimed twofold escalation was both clinically efficacious and non-routine. *Id.* at 13:14-14:5, 19:20-20-22; *see also* Ex. 2007 at 2. This testimony is consistent with the opinions Dr. Baillie expressed in his Supplemental Declaration (Ex. 2305) at ¶¶ 17, 70-75.

Response 2: The testimony cited by Petitioner does not bear on the question of what caused the amelioration of side effects seen by Dr. Rader. Dr. Baillie has maintained that the improved side effect profiles observed by Dr. Rader in his clinical trials (versus those conducted by BMS) cannot be attributed entirely to a low-fat diet, and were instead due to Dr. Rader's novel dosing regimen. Ex. 1060

at 51:20-54:3; Ex. 2305 at ¶¶ 71-74. Dr. Baillie testified that even if the diets in BMS's and Dr. Rader's clinical trials were not identical, all studies employed low-fat diets, and the incidence and severity of adverse events in the BMS trials were shown to be dose-dependent, indicating that adverse effects are related to dose, not solely diet. Ex. 1060 at 40:20-41:14, 50:15-51:19.

Response 3: Petitioner is incorrect that Dr. Baillie “ignore[d] evidence that amelioration of side effects was due to an aggressive restriction of fat in the diet of subjects taking lomitapide.” Dr. Baillie testified that although he considered Exhibit 2079 in forming his opinions, he differed with Petitioner and its experts as to how to interpret the statements in that document. Ex. 1060 at 38:11-40:5. Furthermore, Dr. Baillie did not make “unsubstantiated assumptions” regarding whether the BMS clinical trials with lomitapide employed a low-fat diet. Dr. Baillie based his opinions on internal BMS documents (Ex. 2078 and 2080) that describe the use of low-fat diets in clinical trials that studied the toxicity profile of lomitapide. Ex. 1060 at 30:10-31:7, 32:18-34:17; Ex. 2305 at ¶¶ 73-74; Ex. 2078 at 2-4; Ex. 2080 at 1-2

Response 4: Petitioner mischaracterizes Dr. Baillie's testimony. Dr. Baillie

testified that although a patient undergoing the claimed forced titration method might be subject to a *temporary* dose reduction in the case of toxicity, the patient would still have to complete all of the dosing levels in order to fall within the claims. Ex. 1060 at 10:18-12:23, 44:4-14. Furthermore, Dr. Baillie explained that this forced titration regimen is significantly different from non-forced titrations such as that proposed in Stein (Ex. 1014) and Pink Sheet 2004 (Ex. 1013). *Id.* Dr. Baillie’s testimony is consistent with the opinions expressed in his Supplemental Declaration. Penn Ex. 2305 at ¶¶ 15-16, 24-25, 70.

Response 5: Petitioner is incorrect that Dr. Rader’s citation of Wetterau in Ex. 2077 “contradicts” Dr. Baillie’s opinion regarding lack of reasonable expectation of success. Dr. Baillie testified that in designing his clinical trial, Dr. Rader could not have relied solely on Wetterau’s animal data, especially given Dr. Rader’s access to proprietary BMS human data regarding lomitapide and its adverse event profile. Ex. 1060 at 55:22-58:17; Ex. 2080 at 1-2. This is consistent with Dr. Baillie’s opinion that although Wetterau reports *pharmacodynamic* data, it lacks the necessary *pharmacokinetic* and *toxicology* data a POSA would need to design a safe and effective human dosing regimen for lomitapide. *Id.* at 45:15-47:6; Ex. 2305 at ¶¶ 22-23, 38-39, 52.

Dated: November 10, 2016

Respectfully submitted,
GOODWIN PROCTER LLP

/William G. James/

(Reg. No. 55,931)

GOODWIN PROCTER LLP

901 New York Avenue NW

Washington, DC 20001

Tel: 202-346-4046

Fax: 202-346-4444

wjames@goodwinprocter.com

Attorney for Patent Owner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.